HIV & Aging: Journal Articles

Every two years a group of recognized experts updates a document on recommended antiretroviral drugs for treatment and prevention of HIV . This year’s edition provides a detailed review of the most recent recommendation collected from over 500 sources.

For a number of years HRSA has sponsored the Ryan White HIV/AIDS Program. The funding has focused on HIV management, specifically achieving sustained viral load suppression.  It has been very successful by not only addressing medical issues but also “Wraparound Services” such as  housing, nutrition, case management etc. 

In a study from Madrid 77,590 HIV-positive persons on antiretroviral therapy (ART) were followed for outcomes over 75 days. Of this group, 236 developed documented COVID-19, and 151 were hospitalized.

In a cohort study in New York City 30 hospitalized people living with HIV (PLWH) were compared to 90 similar patients without HIV for effects of COVID-19.

A study from Germany describes the experience of  33 people living with HIV and COVID-19. Just over 90% of the patients recovered with 76% classified as mild. However, 9% died. This frequency of death was higher than the German average of 4%.

A COVID-19 infected hospital cohort in NYC of 21 HIV patients and 42 non-HIV patients was compared. There were no significant differences in ICU admissions, mechanical ventilator use, or deaths between the two groups. 

In a Massachusetts hospital a group of 36 people living with HIV and having COVID-19 was identified. Almost 85% had a comorbidity, such as obesity, cardiovascular disease, or hypertension, and also had severe COVID-19 disease.

A group of 88 people living with HIV (PLH) and hospitalized for COVID-19 in New York City was compared to a similar group with COVID-19 but without HIV.

This document contains over 1000 articles published in 2019 that are pertinent to the domain of HIV AND AGING.

In this 2020 publication the authors identify certain current general antiretroviral therapy (ART) recommendations for use specifically in older adults with HIV. Included are multiple data driven recommendations that can, if used, result in reduced ART toxicities that are associated with elevated frequencies of various diseases and conditions in HIV + older adults.

Pages

Purpose of this Program: The AAHIVM, ACRIA and AGS (collectively, the “Sponsors,” “we” or “us”) are sponsors of this Website and through it seek to address the unique needs and challenges that older adults of diverse populations living with HIV face as they age. However, the information in this Website is not meant to supplant the advice provided in a doctor-patient relationship.

General Disclaimer: HIV-Age.org is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through HIV-Age.org should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1705 DeSales Street NW, Suite 700
Washington, D.C. 20036

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.